STRIDES PHARMA SCI LTD
STAR · Pharma · NSE
₹1,085
Current Market Price
Fair Value (DCF)
₹1,157
Discount to FV
+6.6%
Updated 5h ago
YieldIQ Score
56/100
Piotroski F-Score
6/9
Economic Moat
Moderate
Confidence
29%
ROE
138.9%
Debt/Equity
0.73
WACC
11.1%
Market Cap
₹10,004 Cr
Quality & Valuation
Neutral model outputs — no recommendations.
ROCE
19.9%
Return on capital employed
EV / EBITDA
13.2×
Enterprise multiple
Debt / EBITDA
1.9×
Leverage vs earnings
Interest Coverage
4.7×
EBIT covers interest
Current Ratio
1.25×
Short-term liquidity
Asset Turnover
0.70×
Revenue per ₹ of assets
Revenue CAGR (3Y)
10.4%
3-year revenue growth
Revenue CAGR (5Y)
7.9%
5-year revenue growth
DCF Scenario Analysis
vs CMP ₹1,085.3
Bear case
Margin of Safety -155.6%
Implied upside -60.9%
Base case
Margin of Safety +5.8%
Implied upside +6.2%
Bull case
Margin of Safety +21.3%
Implied upside +27.0%
Ratio Trends
STAR · last 8 annual periods
ROE
138.9%
ROCE
19.9%
Operating Margin
—
Debt / Equity
0.73×
PE
15.9×
EV / EBITDA
22.7×
Historical Financials
STAR · Annual, last 5 years· amounts in ₹Cr unless noted
| Metric | 2022 NSE_XBRL | 2023 NSE_XBRL | 2024 NSE_XBRL | 2025 yfinance | 2026 yfinance | CAGR |
|---|---|---|---|---|---|---|
| Revenue | ₹3022 Cr | ₹3608 Cr | ₹3730 Cr | ₹4565 Cr | ₹4859 Cr | +12.6% |
| EBITDA | ₹-274 Cr | ₹175 Cr | ₹344 Cr | ₹928 Cr | ₹1050 Cr | — |
| EBIT | ₹-365 Cr | ₹260 Cr | ₹373 Cr | — | — | — |
| PAT | ₹-460 Cr | ₹-203 Cr | ₹-70.6 Cr | ₹3593 Cr | ₹556 Cr | — |
| EPS (diluted) | ₹-51.28 | ₹-24.56 | ₹-13.72 | — | — | — |
| CFO | ₹-258 Cr | ₹44.4 Cr | ₹701 Cr | ₹684 Cr | ₹703 Cr | — |
| CapEx | ₹-143 Cr | ₹-94.9 Cr | ₹-118 Cr | ₹-247 Cr | ₹-418 Cr | — |
| FCF | ₹-401 Cr | ₹-50.5 Cr | ₹583 Cr | ₹437 Cr | ₹285 Cr | — |
| Total Assets | ₹6976 Cr | ₹6638 Cr | ₹5840 Cr | ₹6049 Cr | ₹6927 Cr | -0.2% |
| Total Debt | ₹3025 Cr | ₹3030 Cr | ₹2517 Cr | ₹1880 Cr | ₹1758 Cr | -12.7% |
| Shareholders' Equity | ₹2359 Cr | ₹2212 Cr | ₹2126 Cr | ₹2552 Cr | ₹3108 Cr | +7.1% |
CAGR computed across the visible window. Signs reverse if start value is zero or negative.
Peer Comparison
STAR vs 5 closest peers by market-cap band
| Peer | MoS | Score | Verdict | ROE | PE |
|---|---|---|---|---|---|
VIYASH VIYASH SCIENTIFIC LIMITED | -64.7%-39.3% upside | 50 | Above Fair Value | 2.8% | — |
 AKUMS AKUMS | — | — | Pending | 7.7% | — |
PGHL PGHL | — | — | Pending | 3.1% | — |
 SHILPAMED SHILPA MEDICARE LTD | -116.5%-53.8% upside | 40 | Data Limited | 9.8% | — |
SUDEEPPHRM SUDEEPPHRM | — | — | Pending | 28.1% | — |
Click a ticker to view its fair-value analysis.
Dividend History
10 ex-dividend events on file. Source: NSE corporate-actions feed.
Total paid (5Y)
₹10.50/sh
Last payout
2025-07-22
₹4.00
Peak payout
₹12.00
Trailing yield
0.37%
Amounts parsed from NSE subject lines. Percent-of-face-value declarations are converted using the per-ticker face value (defaults to ₹10).
AI Analysis Summary
Model-generated description of metrics. Not investment advice. STRIDES PHARMA SCI LTD (STAR.NS) trades at 1085.30 vs a model fair value of 1157.13, a gap of 6.6%. Piotroski F-score: 6/9. Moat label: M...
Read full AI analysis →Reverse DCF
Market-implied growth
What FCF growth is priced in →
Risk Analysis
Volatility & drawdown
Risk profile of STAR →
DuPont
ROE decomposition
Why ROE is what it is →
Technicals
RSI, MACD, MAs
Reference indicators →
News & Filings
Recent activity
BSE filings + news for STAR →
Compare
Head-to-head with peers
Compare STAR side by side →
Run Full Interactive Analysis
Interactive DCF sliders, sensitivity heatmap, peer comparison, and more.
Analyse STARNow →Model estimates using publicly available data. Not investment advice. YieldIQ is not registered with SEBI as an investment adviser or research analyst. Past performance does not guarantee future results.